Basaloid Squamous Cell Carcinoma: Definition & Outlook

Basaloid squamous cell carcinoma (BSCC) is a rare and aggressive variant of squamous cell carcinoma, a type of cancer arising from the flat cells that line many body surfaces. It most commonly develops in the upper aerodigestive tract, particularly the throat, but can also appear in the esophagus, lungs, and skin. The outlook for someone diagnosed with BSCC depends heavily on where the tumor sits and whether it is linked to human papillomavirus (HPV) infection, a distinction that has reshaped how oncologists think about this cancer over the past decade.

What Makes BSCC Different From Ordinary Squamous Cell Carcinoma

Under the microscope, BSCC looks distinctly different from a standard squamous cell carcinoma. The tumor is biphasic, meaning it contains two cell populations: basaloid cells (which resemble the basal cells found deep in the skin or lining tissues) and squamous cells (the flat, surface-level cells that give squamous cell carcinoma its name).¹ The basaloid cells cluster into solid nests with an exaggerated ratio of nucleus to surrounding cell material, which is what gives them their characteristic dark, “basaloid” appearance. These nests are embedded in dense, scarlike tissue, and deposits of glassy basement-membrane material sometimes appear next to the tumor clusters.²

Several additional patterns help pathologists recognize BSCC. The tumor nests may show comedonecrosis (dead cells in the center of a tumor nest, resembling the core of a blackhead), a cribriform or sieve-like arrangement, and areas of conventional squamous cell carcinoma sitting alongside the basaloid component.³ It is this dual personality that makes diagnosis tricky: BSCC can be confused with adenoid cystic carcinoma, small cell neuroendocrine carcinoma, and several other tumors that share a basaloid look. Accurate identification matters because each of those tumors calls for a different treatment strategy.

Where BSCC Tends to Appear

The vast majority of BSCCs arise in the head and neck region. In a large analysis of the National Cancer Database, the oropharynx (the part of the throat behind the mouth, including the base of the tongue and tonsils) accounted for about 72% of cases, followed by the oral cavity at roughly 12%, the larynx at about 10%, and the hypopharynx at roughly 4%.⁴ A smaller clinical series of 40 cases found a somewhat different distribution, with the larynx and hypopharynx making up the majority, followed by the oropharynx and oral cavity.⁵ The difference likely reflects how much HPV-driven oropharyngeal disease a particular study population captured, since HPV-associated cases overwhelmingly favor the oropharynx.

Outside the head and neck, BSCC also occurs in the esophagus, the lungs, and occasionally the skin or anal canal. These extra-head-and-neck sites are rarer, and each has its own clinical behavior. Esophageal BSCC, for instance, often presents at an advanced stage because difficulty swallowing may not prompt investigation until the tumor is large. Pulmonary BSCC was formally recognized as a distinct subtype in the 2015 World Health Organization classification of lung tumors, which helped standardize how pathologists report it.

Risk Factors and the HPV Divide

Tobacco and alcohol are the traditional risk factors. A review of the literature on oral BSCC found that the majority of affected patients were tobacco and alcohol users.⁶ This mirrors what is known about conventional squamous cell carcinoma throughout the aerodigestive tract: chronic exposure to these carcinogens drives the DNA damage that eventually tips a cell toward cancer.

The more interesting story, however, involves HPV. In oropharyngeal BSCC specifically, HPV positivity is remarkably common. One study found that 75% of oropharyngeal BSCCs tested positive for HPV, while none of the laryngeal or hypopharyngeal tumors did.⁷ A pooled analysis of published data estimated that around 86% of oropharyngeal BSCCs are HPV-positive.⁸ This is a strikingly high rate, and it means that for many patients with oropharyngeal BSCC, the tumor was driven by viral infection rather than by smoking or drinking.

Why does HPV status matter so much? Because HPV-positive BSCCs behave like a fundamentally different disease. In the study that found 75% HPV positivity in oropharyngeal cases, 86% of patients with HPV-positive tumors were alive at three years, compared to only about 35% of those with HPV-negative tumors.⁷ Another study using p16 positivity as a surrogate for HPV found that five-year disease-specific survival was about 73% for p16-positive tumors versus 35% for p16-negative tumors. When both basaloid differentiation and p16 positivity were present, five-year disease-specific survival reached 80%.⁹ These survival gaps are enormous, and they mean that lumping all BSCCs together obscures what is really going on.

Prognosis and the Confusing Survival Data

Ask whether BSCC carries a worse prognosis than conventional squamous cell carcinoma, and you will find conflicting answers in the medical literature. Some of this confusion traces directly to HPV. Older studies, conducted before HPV testing was routine, tended to show BSCC behaving more aggressively. One European case-control study of 62 patients found that survival was significantly lower in BSCC compared to matched conventional squamous cell carcinoma, with a distant metastasis rate six times higher in BSCC patients.¹⁰ Another early study noted that even small BSCCs tended to recur at distant sites rather than locally.¹¹

Yet other studies found no survival difference at all. A comparison of oral BSCC with poorly differentiated and moderately differentiated squamous cell carcinomas found five-year cancer-specific survival rates of about 50%, 37%, and 49%, respectively, with no statistically significant gap between the groups.¹² A study of patients treated with radiotherapy found that five-year disease-free and overall survival rates for BSCC were statistically comparable to those for poorly differentiated and moderately differentiated squamous cell carcinoma, with five-year overall survival for BSCC patients reaching about 85%.¹³

The most likely explanation for the discrepancy is that studies with high proportions of HPV-positive oropharyngeal cases naturally show better outcomes, while studies dominated by HPV-negative tumors in the larynx, hypopharynx, or oral cavity report worse survival. When researchers started separating HPV-positive from HPV-negative cases, the picture became clearer: HPV-positive oropharyngeal BSCC has a favorable prognosis, often better than many head and neck cancers, while HPV-negative BSCC at any site remains an aggressive disease with a strong tendency to spread to distant organs.

Distant Metastasis and Why It Matters

One of the clinical hallmarks that first earned BSCC its aggressive reputation is its tendency to metastasize to distant sites. While conventional squamous cell carcinoma of the head and neck most often recurs locally or in regional lymph nodes, BSCC shows a disproportionate tendency to spread to the lungs, liver, and bones. The six-fold higher distant metastasis rate reported in the European case-control study underscores this pattern.¹⁰ This was, in fact, the major driver of mortality in that series.

The distant metastasis tendency is thought to relate to the molecular biology of the basaloid component. Research on esophageal BSCC has found upregulation of genes associated with epithelial-mesenchymal transition, a process in which tumor cells acquire the ability to migrate and invade distant tissues.¹⁴ This molecular signature may help explain why BSCC seems biologically primed to escape its site of origin, even when the primary tumor is caught relatively early.

Treatment Approaches

Because BSCC is rare, there is no single large randomized trial dictating treatment. In practice, management largely follows the same principles used for conventional squamous cell carcinoma at the same anatomical site: surgery when feasible, followed by radiation with or without chemotherapy depending on the stage and risk features.

For early-stage tumors, surgery alone may be sufficient. A recent case of BSCC on the tongue, staged as pT2 with a shallow depth of invasion and clear surgical margins, was managed with a partial glossectomy and surveillance without adjuvant therapy.¹⁵ Such conservative management is only an option when the pathology report shows favorable features, including clear margins and limited depth of invasion.

For more advanced tumors, radiation plays a central role. In the study of radiotherapy outcomes in head and neck BSCC, patients received treatment similar to what would be given for conventional squamous cell carcinoma, including a median radiation dose of 70 Gray, with some receiving concurrent or induction chemotherapy.¹³ There is some evidence that BSCC may be particularly sensitive to radiation. An 85-year-old man with advanced esophageal BSCC (stage III) who was treated with radiation alone, having refused surgery, remained alive and recurrence-free two years after completing treatment.¹⁶ While a single case is far from proof, it supports the idea that BSCC may respond well to radiation, making it a viable option for patients who cannot tolerate surgery.

In the esophagus, endoscopic removal of superficial BSCC followed by chemoradiotherapy has shown promise. Two reported cases of esophageal BSCC treated with endoscopic submucosal dissection and additional chemoradiotherapy achieved long-term survival, suggesting that less invasive approaches may work when the disease is caught early and confined to the surface layers.¹⁷

BSCC in the Lungs

Pulmonary BSCC is a distinct entity with its own imaging characteristics. On CT scans, these tumors usually appear as solitary nodules or masses, often in the range of one to five centimeters. They tend to show low to intermediate density and moderate enhancement after contrast injection.¹⁸ One feature that helps radiologists distinguish pulmonary BSCC from ordinary lung squamous cell carcinoma is the absence of cavitation: while conventional squamous cell carcinoma of the lung frequently develops a hollowed-out center on imaging, basaloid squamous cell carcinoma typically does not. Endobronchial growth (the tumor pushing into the airway) and associated collapse or infection of the lung beyond the blockage are also more common in BSCC than in non-basaloid lung squamous cell carcinoma.¹⁹

The practical value of recognizing these imaging patterns is that they can raise suspicion early and guide biopsy. A solid lung nodule without cavitation in a smoker might trigger consideration of BSCC alongside the more common diagnoses. From a treatment standpoint, a case report documented a patient with stage IV lung BSCC who responded to combined chemotherapy and immunotherapy with carboplatin, nab-paclitaxel, and pembrolizumab, remaining in partial remission on maintenance immunotherapy despite a PD-L1-negative tumor.²⁰ A single case cannot guide practice, but it raises interesting questions about whether immunotherapy might have a role in pulmonary BSCC even when standard biomarkers predict it would not work.

Molecular Landscape and Emerging Therapies

Research into the molecular machinery of BSCC has identified several potential therapeutic targets, particularly in esophageal tumors. About half of esophageal BSCCs carry either a mutation or amplification of EGFR, the epidermal growth factor receptor, and these alterations tend to occur in a mutually exclusive fashion. The Wnt and Hedgehog signaling pathways, both involved in cell growth and development, are also frequently activated in these tumors.²¹ These are pathways for which drugs already exist in other cancer settings, making them logical candidates for investigation in BSCC.

A more nuanced molecular picture has also emerged. Integrated characterization of esophageal BSCC found no major genetic mutations that were unique to BSCC compared to conventional esophageal squamous cell carcinoma. The differences were instead at the level of gene expression: BSCC showed increased activity in genes related to blood-vessel formation, basement-membrane components, and the migration-promoting epithelial-mesenchymal transition pathway, while genes linked to squamous differentiation and immune signaling were turned down. A staining test for SFRP1 protein proved highly sensitive and specific for diagnosing BSCC, offering a practical tool for pathologists.¹⁴

The immune landscape of BSCC carries important implications for immunotherapy. A study comparing esophageal BSCC to conventional esophageal squamous cell carcinoma in patients treated with a combination of chemotherapy and immunotherapy before surgery found that the basaloid subtype responded far less well. Only about 18% of basaloid ESCC patients showed an effective response (defined as less than 10% residual tumor in the esophageal wall), compared to about 59% for conventional ESCC. The basaloid tumors displayed features of an immune “cold” environment: fewer immune cells infiltrating the tumor, fewer immune-cell clusters at the tumor boundary, and lower expression of PD-L1, the protein that many checkpoint immunotherapy drugs target.²² This finding is sobering, because it suggests that the immunotherapy revolution transforming outcomes in many cancers may not extend equally to BSCC of the esophagus.

Skin BSCC and Non-Mucosal Sites

While head-and-neck and esophageal BSCC get the most attention in the literature, this variant also occurs on the skin, where it can mimic basal cell carcinoma under the microscope. Cutaneous BSCC shares the same defining histologic features seen in mucosal sites: basaloid tumor nests with a high nuclear-to-cytoplasmic ratio, fibrotic stroma, glassy deposits of basement-membrane material, and peripheral palisading of cells at the edges of the nests.² The critical difference is that basal cell carcinoma, despite its similar name, is a far less aggressive cancer with an extremely low metastatic potential. Misdiagnosing a cutaneous BSCC as a basal cell carcinoma could lead to inadequate treatment and a missed opportunity to catch spread early.

BSCC has also been reported in the anal canal, where it can adopt an adenoid-cystic-like pattern that complicates diagnosis further. Because true adenoid cystic carcinoma has a different biology and treatment paradigm, distinguishing these look-alikes through immunohistochemistry is essential to getting the right diagnosis and the right treatment plan.

Why Accurate Subtyping Matters for Patients

BSCC sits at a crossroads of several diagnostic and prognostic challenges that directly affect patients. The first is the diagnostic challenge itself. Because BSCC can resemble several other tumor types, the initial biopsy may return an incorrect label. The consequences cascade: adenoid cystic carcinoma, for instance, tends to grow slowly along nerves and is usually treated with wide surgical excision, while BSCC is more likely to metastasize distantly and often calls for radiation-based treatment. Getting the pathology wrong means getting the treatment wrong.

The second is HPV testing. For any BSCC arising in the oropharynx, HPV status is arguably the single most important prognostic factor. Patients with HPV-positive oropharyngeal BSCC have survival rates that rival or exceed those of many other head and neck cancers, while HPV-negative patients face a much grimmer outlook. This distinction is increasingly guiding clinical trials exploring whether HPV-positive patients can receive less intensive treatment to reduce long-term side effects without sacrificing cure rates.

The third is the question of immunotherapy eligibility. As checkpoint inhibitors become standard in many squamous cell carcinomas, the evidence that esophageal BSCC behaves as an immune “cold” tumor raises important questions. A patient with esophageal BSCC might be offered immunotherapy based on protocols designed for conventional esophageal squamous cell carcinoma, but the response rates appear markedly lower.²² How this finding will shape treatment recommendations in the coming years remains to be seen, but it underscores that treating BSCC as if it were simply another squamous cell carcinoma risks missing biologically meaningful differences that affect how well a given therapy works.